Impacts of statin and metformin on neuropathy in patients with type 2 diabetes mellitus: Korean Health Insurance data

被引:0
|
作者
Hong Ki Min [1 ]
Se Hee Kim [1 ]
Jong Han Choi [1 ]
Kyomin Choi [2 ]
Hae-Rim Kim [3 ]
Sang-Heon Lee [3 ]
机构
[1] Department of Internal Medicine, Konkuk University Medical Center
[2] Department of Neurology, Konkuk University Medical Center
[3] Division of Rheumatology, Department of Internal Medicine,Konkuk University School of Medicine
关键词
D O I
暂无
中图分类号
R587.2 [糖尿病性昏迷及其他并发症];
学科分类号
1002 ; 100201 ;
摘要
BACKGROUND Neuropathy is a common chronic complication in type 2 diabetes mellitus(T2DM). Statin and metformin are commonly used medications in T2DM patients, and some studies showed statin-or metformin-induced neuropathy.AIM To evaluate the incidence of neuropathy among patients with T2DM associated with statin and metformin therapies.METHODS Korean Health Insurance Review and Assessment national patient sample data from 2016 and 2017 were used. Patients with T2 DM and no complications were divided into statin/metformin/statin + metformin users and non-users. Neuropathy incidence was defined by International Statistical Classification of Diseases and Related Health Problems, 10 th revision codes and concomitant prescriptions for anticonvulsants or antidepressants. Logistic regression analyses were conducted to examine the associations between statin/metformin/statin + metformin therapies and the incidence of neuropathy. Propensity score(PS) matching was performed on the basis of age, sex and comorbidities.RESULTS Overall, 34964 and 35887 patients with T2DM and no complications were included in the Korean Health Insurance Review and Assessment national patient sample datasets from 2016 and 2017, respectively. Statin therapy was associated with increased risks of neuropathy in 2016 and 2017 [PS-matched odds ratio(OR) = 1.22, 95% confidence interval(CI): 1.08-1.38; PS-matched OR = 1.17, 95%CI: 1.03-1.33, respectively]. Metformin therapy was associated with reduced risks of neuropathy in 2016 and 2017(PS-matched OR = 0.30, 95%CI: 0.21-0.42; PSmatched OR = 0.44, 95%CI: 0.32-0.60, respectively). Combined statin + metformin therapy was not significantly associated with neuropathy in 2016 or 2017(PSmatched OR = 0.85, 95%CI: 0.61-1.19; PS-matched OR = 0.95, 95%CI: 0.66-1.38, respectively).CONCLUSION Statin therapy was associated with enhanced risk of new-onset neuropathy in patients with T2DM, but metformin therapy showed the opposite association.
引用
收藏
页码:10198 / 10207
页数:10
相关论文
共 50 条
  • [21] Metformin Use and Leukemia Risk in Patients With Type 2 Diabetes Mellitus
    Tseng, Chin-Hsiao
    FRONTIERS IN ENDOCRINOLOGY, 2020, 11
  • [22] Metformin in patients with type 2 diabetes mellitus and heart failure: a review
    Kulaczkowska, Zofia M.
    Wrobel, Marta
    Rokicka, Dominika
    Gasior, Mariusz
    Strojek, Krzysztof
    ENDOKRYNOLOGIA POLSKA, 2021, 72 (02) : 163 - 170
  • [23] Metformin and Risk of Hypertension in Taiwanese Patients With Type 2 Diabetes Mellitus
    Tseng, Chin-Hsiao
    JOURNAL OF THE AMERICAN HEART ASSOCIATION, 2018, 7 (13):
  • [24] Contraindications to metformin therapy among patients with type 2 diabetes mellitus
    Waleed M. Sweileh
    Pharmacy World & Science, 2007, 29 : 587 - 592
  • [25] Population Pharmacokinetics of Metformin in Mexican Patients with Type 2 Diabetes Mellitus
    Barranco Garduno, L. M.
    Neri Salvador, J. C.
    Juarez Olguin, H.
    Lugo Goytia, G.
    Carrasco Portugal, M.
    Flores Murrieta, F.
    INTERNATIONAL JOURNAL OF PHARMACOLOGY, 2015, 11 (06) : 632 - 637
  • [26] Metformin and lung cancer risk in patients with type 2 diabetes mellitus
    Tseng, Chin-Hsiao
    ONCOTARGET, 2017, 8 (25) : 41132 - 41142
  • [27] Population pharmacokinetics of metformin in obese patients with type 2 diabetes mellitus
    Bardin, C.
    Nobecourt, E.
    Larger, E.
    Chast, F.
    Treluyer, J.
    Urien, S.
    FUNDAMENTAL & CLINICAL PHARMACOLOGY, 2011, 25 : 79 - 79
  • [28] Contraindications to metformin therapy among patients with type 2 diabetes mellitus
    Sweileh, Waleed M.
    PHARMACY WORLD & SCIENCE, 2007, 29 (06): : 587 - 592
  • [29] The relationship between exacerbated diabetic peripheral neuropathy and metformin treatment in type 2 diabetes mellitus
    Hashem, Manal Mohammed
    Esmael, Ahmed
    Nassar, Abdelfattah Kasem
    El-Sherif, Mohammed
    SCIENTIFIC REPORTS, 2021, 11 (01)
  • [30] The relationship between exacerbated diabetic peripheral neuropathy and metformin treatment in type 2 diabetes mellitus
    Manal Mohammed Hashem
    Ahmed Esmael
    Abdelfattah Kasem Nassar
    Mohammed El-Sherif
    Scientific Reports, 11